Antengene Corporation Limited (06996.HK): Expected to Swing to Profit in Interim Period, Revenue to Hit RMB 490 Million to RMB 536 Million

NewTimeSpace News: On July 28, 2026, Antengene Corporation Limited (06996.HK) issued a positive profit forecast. It expects interim revenue of approximately RMB 490 million to RMB 536 million, representing a sharp year-on-year surge, and profits of RMB 195 million to RMB 238 million, marking a turnaround from loss to profit.

The announcement noted that the growth in revenue and profits is mainly attributable to two partnership deals. First, the out-licensing and collaboration arrangement with UCB for ATG-201 (CD19×CD3), effective March 2026, brought an upfront payment of USD 60 million. Second, the exclusive out-licensing and cooperation agreement with K2 Therapeutics for ATG-106 (CDH6×CD3), effective June 2026, generated additional income.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.